Business Context and Reporting Period
This Form 8-K, dated April 4, 2019, reports on the special meeting of stockholders held by Vital Therapies, Inc. The filing details the approval of a business combination with Immunic AG, resulting in a change of control and a corporate name change to Immunic, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and voting results.
Material Changes
The following material changes were approved by stockholders at the special meeting:
- Change in Control: Approval of an Exchange Agreement with Immunic AG, resulting in a change of control of Vital Therapies.
- Corporate Name Change: Approval to change the corporate name from Vital Therapies, Inc. to Immunic, Inc.
- Reverse Stock Split: Approval of a reverse stock split of outstanding common stock within a range of 30 to 60 shares for every one new share.
- Stock Issuance: Approval of the issuance of common stock to shareholders of Immunic AG pursuant to the Exchange Agreement.
Voting Results and Management Commentary
At the special meeting, 23,699,850 shares (approximately 55.93% of outstanding common stock entitled to vote) were represented. All four proposals were approved. The specific voting results were:
| Proposal | For | Against | Abstain |
|---|---|---|---|
| 1. Issuance of Common Stock | 23,356,120 | 277,127 | 66,603 |
| 2. Change in Control | 23,359,988 | 269,057 | 70,805 |
| 3. Name Change to Immunic, Inc. | 23,470,789 | 160,742 | 68,319 |
| 4. Reverse Stock Split (30-60:1) | 23,083,215 | 532,540 | 84,095 |
The filing notes that an adjournment to solicit additional proxies was deemed unnecessary as all proposals passed.
Investor Verification Checklist
- Verify the final ratio of the reverse stock split (approved range was 30 to 60 shares for 1) in subsequent filings.
- Confirm the effective date of the name change to Immunic, Inc. and the ticker symbol change.
- Review the definitive proxy statement/prospectus filed on February 19, 2019, for details on the Exchange Agreement terms.
- Monitor the issuance of new shares to Immunic AG shareholders and the resulting capital structure.